PodcastThe Directors The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentumAs oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic July 18, 2025Vol.51 No.28By Paul Goldberg and Katie Goldberg
Regulatory News ODAC nixes GSK’s Blenrep myeloma regimens, citing ocular toxicity, dosing, applicability to U.S. population July 18, 2025Vol.51 No.28By Jacquelyn Cobb and Sara Willa Ernst
Sponsored Imaging’s ride to the bottom in clinical trials—and why it matters now July 18, 2025Vol.51 No.28By Jeff Sorenson
First-ever financial toxicity tumor board aims to change the standard of careResearchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI July 11, 2025Vol.51 No.27By Claire Marie Porter
Conversation with The Cancer Letter HHS seems poised to exert control over USPSTFRansohoff: The task force is the pinnacle of evidence-based medicine July 11, 2025Vol.51 No.27By Paul Goldberg
Guest Editorial Understanding the impact of the Israeli-U.S. attacks on Iran’s nuclear facilities July 11, 2025Vol.51 No.27By Robert Peter Gale
Trials & Tribulations An overlooked immune cell population may offer new direction for cell and gene therapy July 11, 2025Vol.51 No.27By Arthur Machlenkin
Sponsored Unraveling connections between diabetes and cancer: Insights from metabolism research at City of Hope July 11, 2025Vol.51 No.27By Charles Brenner
FreeIn the Archives Rick and Mary Pazdur on facing “the other side of the stethoscope”A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology July 11, 2025Vol.51 No.27By Katie Goldberg
She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research July 03, 2025Vol.51 No.26By Jacquelyn Cobb
